170 related articles for article (PubMed ID: 34583727)
21. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic.
Shabason JE; Tofilon PJ; Camphausen K
J Cell Mol Med; 2011 Dec; 15(12):2735-44. PubMed ID: 21362133
[TBL] [Abstract][Full Text] [Related]
22. Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme.
Choi J; Kim G; Cho SB; Im HJ
J Nanobiotechnology; 2020 Sep; 18(1):122. PubMed ID: 32883290
[TBL] [Abstract][Full Text] [Related]
23. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P
Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992
[TBL] [Abstract][Full Text] [Related]
24. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Bezecny P
Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
[TBL] [Abstract][Full Text] [Related]
26. A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme.
Julka PK; Awasthy BS; Rath GK; Agarwal S; Varna T; Mahapatra AK; Singh R
Australas Radiol; 2000 Feb; 44(1):84-7. PubMed ID: 10761264
[TBL] [Abstract][Full Text] [Related]
27. Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.
Kong L; Gao J; Hu J; Lu R; Yang J; Qiu X; Hu W; Lu JJ
Cancer Commun (Lond); 2019 Feb; 39(1):5. PubMed ID: 30786916
[TBL] [Abstract][Full Text] [Related]
28. Editorial: Hypoxic cell radiosensitizers.
Belli JA; Hellman S
N Engl J Med; 1976 Jun; 294(25):1399-400. PubMed ID: 177876
[No Abstract] [Full Text] [Related]
29. microRNAs: Potential glioblastoma radiosensitizer by targeting radiation-related molecular pathways.
Bahreyni-Toossi MT; Dolat E; Khanbabaei H; Zafari N; Azimian H
Mutat Res; 2019 Nov; 816-818():111679. PubMed ID: 31715522
[TBL] [Abstract][Full Text] [Related]
30. Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo.
Yacoub A; Mitchell C; Lister A; Lebedeva IV; Sarkar D; Su ZZ; Sigmon C; McKinstry R; Ramakrishnan V; Qiao L; Broaddus WC; Gopalkrishnan RV; Grant S; Fisher PB; Dent P
Clin Cancer Res; 2003 Aug; 9(9):3272-81. PubMed ID: 12960112
[TBL] [Abstract][Full Text] [Related]
31. Halogenated pyrimidines as radiosensitizers for high grade glioma: revisited.
Rodriguez R; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):859-62; discussion 865. PubMed ID: 1651310
[No Abstract] [Full Text] [Related]
32. CD44-associated radioresistance of glioblastoma in irradiated brain areas with optimal tumor coverage.
Liu WH; Lin JC; Chou YC; Li MH; Tsai JT
Cancer Med; 2020 Jan; 9(1):350-360. PubMed ID: 31746135
[TBL] [Abstract][Full Text] [Related]
33. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.
Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310
[TBL] [Abstract][Full Text] [Related]
34. Modulation of Sonic hedgehog signaling and WW domain containing oxidoreductase WOX1 expression enhances radiosensitivity of human glioblastoma cells.
Chiang MF; Chen HH; Chi CW; Sze CI; Hsu ML; Shieh HR; Lin CP; Tsai JT; Chen YJ
Exp Biol Med (Maywood); 2015 Mar; 240(3):392-9. PubMed ID: 25595187
[TBL] [Abstract][Full Text] [Related]
35. Hypoxic cell radiosensitizers in the treatment of malignant brain tumors.
Gutin PH; Wara WM; Phillips TL; Wilson CB
Neurosurgery; 1980 May; 6(5):567-76. PubMed ID: 6251398
[TBL] [Abstract][Full Text] [Related]
36. DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma.
Roberto GM; Paiva HH; Botelho de Souza LE; Pezuk JA; Vieira GM; de Oliveira HF; Umezawa K; Tone LG; Brassesco MS
Anticancer Agents Med Chem; 2018; 18(9):1323-1329. PubMed ID: 29683097
[TBL] [Abstract][Full Text] [Related]
37. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936
[TBL] [Abstract][Full Text] [Related]
38. Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity.
Martin JG; Ward JA; Feyertag F; Zhang L; Couvertier S; Guckian K; Huber KVM; Johnson DS
Chembiochem; 2021 Jun; 22(12):2116-2123. PubMed ID: 33887086
[TBL] [Abstract][Full Text] [Related]
39. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.
Yang YP; Chang YL; Huang PI; Chiou GY; Tseng LM; Chiou SH; Chen MH; Chen MT; Shih YH; Chang CH; Hsu CC; Ma HI; Wang CT; Tsai LL; Yu CC; Chang CJ
J Cell Physiol; 2012 Mar; 227(3):976-93. PubMed ID: 21503893
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
